SDHAF2 and neoplasm: More importantly, the patients with SDH5 deficiency had better survival (average median progression-free survival (PFS): 30.0 versus 15.0 months, hazard ratio: 0.276, 95% confidence interval: 0.201-0.379, log-rank test, P<0.001; average median overall survival (OS) 38.0 versus 25.0 months, hazard ratio: 0.471, 95% confidence interval: 0.355-0.626, log-rank test, P<0.001), and the results from the plasma and tumor samples were consistent (Figure 1J).